This past week, DeNovX conducted site visits, technology updates, and data collection with its strategic partners at the Advanced Photon Source at Argonne National Laboratory and at the Stanford Synchrotron Radiation Lightsource at SLAC National Accelerator Laboratory. DeNovX is developing a reproducible high throughput synchrotron powder X-ray diffraction workflow to support pharmaceutical development under a Phase II SBIR grant from the National Institutes of Health. The interdisciplinary team comprising chemists, physicists, engineers, and crystallographers has progressed through prototyping, reproducibility studies, and rigorous method qualification studies and is now demonstrating benefits that include rapid data collection requiring a fraction of the [...]
Thanks to an NIH Phase I SBIR award, DeNovX is expanding its collaboration with researchers at Argonne National Laboratory’s Biosciences Division to enhance protein crystal production for the Advanced Photon Source. Serial macromolecular crystallography for protein structure determination permits data collection on small and/or radiation sensitive crystals at room temperature using highly intense X-rays. Serial crystallography is increasingly used in structural biology, and DeNovX is focused on integrating the company’s engineered nucleation feature products into crystallization pipelines to generate more protein crystals at a faster rate in support of structure-based drug design.
Thanks to a longstanding collaboration with Argonne’s Midwest Center for Structural Genomics and the Center for Structural Genomics of Infectious Diseases, the crystal structure of a siderophore binding protein FatB from Desulfitobacterium hafniense has been determined and deposited with the Protein Data Bank (7SF6). This protein was crystallized in the DeNovX laboratories during quantitative crystallization studies and multiple diffraction quality crystals were reproducibly formed on select engineered nucleation features while the control studies produced just a few poorly diffracting crystals. This novel crystallization and structure determination adds to the list of benefits of using DeNovX’s engineered nucleation features that include [...]
DeNovX is pleased to announce that it has executed a collaborative agreement to advance the development of high throughput compressive cocrystallization with detection by synchrotron powder X-ray diffraction with SLAC National Accelerator Laboratory, which is operated by Stanford University for the Department of Energy. This effort targets improvements to the solubility and bioavailability of active pharmaceutical ingredients, and it is sponsored by the National Institutes of Health through a Phase II SBIR award to DeNovX.
As part of a Phase II SBIR award from the National Institutes of Health to DeNovX, a strategic partnership has been formalized between DeNovX and the X-ray Sciences Division at Argonne National Laboratory, which is operated by The University of Chicago for the United States Department of Energy. The goal of this work is to improve the solubility and bioavailability of small molecule active pharmaceutical ingredients and cocrystals by developing new high throughput screening discovery techniques that can fully leverage the analytical capabilities of synchrotron X-ray powder diffraction.
In March of this year, DeNovX and MIT finalized details of a collaborative agreement to continue development of patented continuous flow crystallization methods. This effort is sponsored by the National Institutes of Health through a Phase II SBIR award to DeNovX, and the work seeks to improve manufacturing-scale crystallization of pharmaceuticals by leveraging the unparalleled efficiency and safety advantages of continuous flow manufacturing.
DeNovX has received the exciting news that its company-owned patents for improving crystallization using engineered nucleation features have been granted by the European and Canadian patent offices. These patents add to the already issued patents in the US and Japan (below), signalling broad coverage in those jurisdictions in which crystallization is an important process in the pharmaceutical, food, cosmetic, agricultural, fine chemical, and bioengineering fields that stand to benefit from these crystal nucleation technologies